Statement of Changes in Beneficial Ownership (4)
18 November 2021 - 9:19AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
LOUMEAU ERIC J |
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC
[
ANAB
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) COO, General Counsel |
(Last)
(First)
(Middle)
C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/15/2021 |
(Street)
SAN DIEGO, CA 92121
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 11/15/2021 | | A | | 523 (1) | A | $22.03 | 523 (2) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Represents shares of Common Stock acquired pursuant to the Issuer's Employee Stock Purchase Plan ("ESPP"), for the purchase period through November 15, 2021. In accordance with the ESPP, these shares were purchased at 85% of the lesser of the closing price of the Issuer's Common Stock on May 17, 2021 and November 15, 2021. |
(2) | In addition to the reporting person's common stock directly held as set forth in Table I above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 230,500 shares of common stock, which options vest according to their terms. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
LOUMEAU ERIC J C/O ANAPTYSBIO, INC. 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO, CA 92121 |
|
| COO, General Counsel |
|
Signatures
|
/s/ Eric Loumeau | | 11/17/2021 |
**Signature of Reporting Person | Date |
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2023 to Apr 2024